Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366938 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,464
- Enrollment target
NCT00366938: Completed Phase 3 study, sponsored by Novartis.
NCT00366938 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,464 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00366938, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,464 participants
- Enrollment target
Study Summary
This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).
Interventions
- DRUG Lumiracoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,464 participants |
| Start Date | 2003-09 |
| Phase | Phase 3 |
What the finished NCT00366938 record still lists
NCT00366938 is an interventional study that assigns participants to a tested intervention. Its 1,464 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 1 intervention - of which Lumiracoxib is the first listed.
NCT00366938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00366938 about?
NCT00366938 is a clinical study titled "Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).". This study will investigate the efficacy and safety of lumiracoxib in patients with primary knee osteoarthritis (OA).
What is the current status of trial NCT00366938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,464 participants. The study started on 2003-09.
What interventions are being tested in trial NCT00366938?
The interventions under investigation include: Lumiracoxib (DRUG).
Who is sponsoring clinical trial NCT00366938?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00366938's enrollment target sits among peer trials
1,464 164th of 2000 higher than 1,837 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia